![]() In the same year, Augustin Barruel’s “Memoirs Illustrating the History of Jacobinism” came out, which promoted the theory that secret societies – including the Illuminati – were behind the French Revolution. The Illuminati then became one of the oldest conspiracy theories when in 1797, physicist John Robison published “Proofs of a Conspiracy”, a polemic book that accused the Illuminati of infiltrating the Freemasonry. Therefore, the ‘lluminatenorden’ sought to promote secular, intellectual, and philanthropic values among elites to influence decision-making. Historically, the Order of the Illuminati referred to a secret society that operated from 1776 to 1785, founded in Bavaria by Adam Weishaupt, a German philosopher and law professor who was strongly inspired by Enlightenment ideals. The ‘Illuminati’ conspiracy falls under this category and is at the centre of our investigation. identifier: NCT02264574.In her conspiracy chart, misinformation researcher Abbie Richards places at the highest level of detachment from reality beliefs that “the world is ruled by a supreme shadow elite”, which thus are the most dangerous. In this final analysis with up to 52 months of follow-up (median 45 months), ibrutinib plus obinutuzumab showed sustained clinical benefit, in terms of progression- free survival, in first-line treatment of chronic lymphocytic leukemia, including in patients with high-risk features. As is typical for ibrutinib-based regimens, common grade ≥3 adverse events were most prevalent in the first 6 months of ibrutinib plus obinutuzumab treatment and generally decreased over time, except for hypertension. With a median treatment duration of 42 months, 13 months longer than the primary analysis, no new safety signals were identified for ibrutinib. The best overall rate of undetectable minimal residual disease (<0.01% by flow cytometry) remained higher with ibrutinib plus obinutuzumab (38%) than with chlorambucil plus obinutuzumab (25%). After a median follow-up of 45 months (range, 0.2-52), median progression-free survival continued to be significantly longer in the ibrutinib plus obinutuzumab arm than in the chlorambucil plus obinutuzumab arm (median not reached versus 22 months hazard ratio=0.25 95% confidence interval: 0.16-0.39 P<0.0001). Patients received oral ibrutinib 420 mg once daily until disease progression or unacceptable toxicity or six cycles of oral chlorambucil, each in combination with six cycles of intravenous obinutuzumab. Eligible patients were aged ≥65 years, or <65 years with coexisting conditions. ILLUMINATE is a randomized, open-label phase III study of ibrutinib plus obinutuzumab (n=113) versus chlorambucil plus obinutuzumab (n=116) as first-line therapy for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. ![]() 13 Sarah Cannon Research Institute, Nashville, TN, USA. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |